The current advances of CRISPR/Cas-based systems for the detection of COVID-19

The novel coronavirus disease 2019 (COVID-19) still poses a serious threat to every human on the planet nearly 1.5 years after its beginning. Unfortunately, the current diagnostic methods, although highly sensitive and specific, still suffer from many shortcomings. Faster and easy-to-operate diagnostic systems are undoubtedly sorely needed. The CRISPR/Cas platform has gained much attention in recent years in a wide range of biomedical sciences. Besides its treatment potential and drug and vaccine development, it can be used for disease diagnosis. Thus, the CRISPR/Cas-based system holds great promise for providing a rapid and easily deployable COVID-19 detection and is on par with the conventional diagnostic approaches in terms of sensitivity and specificity. In this review article, we discuss the latest advances of CRISPR/Cas technology as a fast and reliable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection method

Healthy Male Individuals Possess Higher Plasma HER-2 Level than Females

Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serumlevels of HER2, in this paper we tried to highlight the issue that most studies don’t stratify the HER-2 concentrationof individuals in terms of gender. In this brief survey, healthy individuals with no prior non-communicable diseaseswere categorized as males (n=34) and females (n=43), and all samples were evaluated for plasma HER-2 levelsat once. Surprisingly, the plasma level of HER-2 of healthy male individuals (mean= 2.28 ± 0.21 ng/mL) wassignificantly (P<0.0001) higher than the plasma level of HER-2 of healthy females (mean: 0.06 ± 0.09 ng/mL),with no overlap. Therefore, we suggest that more studies are required to re-check the cutoff values for HER-2plasma levels based on gender since the clinical implications of a unique HER-2 cutoff for both genders may beseriously concerning

Data_Sheet_1_Insights into additional lactone-based signaling circuits in Streptomyces: existence of acyl-homoserine lactones and LuxI/LuxR homologs in six Streptomyces species.zip

Acyl-homoserine lactones (AHLs), mediating pivotal physiological activities through quorum sensing (QS), have conventionally been considered limited to Gram-negative bacteria. However, few reports on the existence of AHLs in Gram-positive bacteria have questioned this conception. Streptomyces, as Gram-positive bacteria already utilizing a lactone-based QS molecule (i.e., gamma-butyrolactones), are yet to be explored for producing AHLs, considering their metabolic capacity and physiological distinction. In this regard, our study examined the potential production of AHLs within Streptomyces by deploying HPLC-MS/MS methods, which resulted in the discovery of multiple AHL productions by S. griseus, S. lavendulae FRI-5, S. clavuligerus, S. nodosus, S. lividans, and S. coelicolor A3(2). Each of these Streptomyces species possesses a combination of AHLs of different size ranges, possibly due to their distinct properties and regulatory roles. In light of additional lactone molecules, we further confirm that AHL- and GBL-synthases (i.e., LuxI and AfsA enzyme families, respectively) and their receptors (i.e., LuxR and ArpA) are evolutionarily distinct. To this end, we searched for the components of the AHL signaling circuit, i.e., AHL synthases and receptors, in the Streptomyces genus, and we have identified multiple potential LuxI and LuxR homologs in all 2,336 Streptomyces species included in this study. The 6 Streptomyces of interest in this study also had at least 4 LuxI homologs and 97 LuxR homologs. In conclusion, AHLs and associated gene regulatory systems could be more widespread within the prokaryotic realm than previously believed, potentially contributing to the control of secondary metabolites (e.g., antibiotics) and their complex life cycle, which leads to substantial industrial and clinical applications.</p